Rho will highlight its regulatory expertise to accelerate the drug review and approval process at the Innovative Regulatory Pathways Summit, taking place on January 29-30 in Arlington, Virginia.
WHAT:
Rho, a full-service contract research organization (CRO), will highlight its regulatory expertise to accelerate the drug review and approval process at the Innovative Regulatory Pathways Summit, taking place on January 29-30 in Arlington, Virginia.
David Shoemaker, Rho’s senior vice president of Research & Development, will offer his expertise in pharmaceutical product development, as well as highlight his involvement with ensuring products meet regulatory standards at all stages of the development process.
Rho focuses on helping pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, including clinical operations, project management, data management, data standards, and biostatistics, with extensive experience in many therapeutic areas.
WHO:
Rho expert at the Innovative Regulatory Pathways Summit:
David Shoemaker, Senior Vice President, Research & Development
WHEN:
January 29-30, 2018
WHERE:
Hilton Crystal City at Reagan National Airport 2399 Jefferson Davis Hwy Arlington, VA 22202
DETAILS:
For media inquiries, please contact Kelly Maicon at Largemouth Communications, 919.741.9784, kmaicon@largemouthpr.com.
ABOUT:
Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 34 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter.
